MRKR - Marker Therapeutics to raise funds via $25M share sale

• Immuno-oncology company Marker Therapeutics ( NASDAQ: MRKR ) has entered into a common stock purchase agreement with Lincoln Park Capital Fund, under which the latter will purchase up to $25M of shares of the company's common stock over a 24-month period.
• Marker ( MRKR ) anticipates using proceeds from sales of shares to advance the Phase 2 ARTEMIS trial of its lead product candidate in post-transplant AML, MT-401, its clinical programs in lymphoma and pancreatic cancer, and for working capital and general corporate purposes.
• MRKR shares were up 9% premarket on Tuesday

For further details see: